Background Slow progress in improving the outcome of ovarian with chemotherapy over the last decade has stimulated research into molecularly targeted therapy. PARP inhibitors target DNA repair and are specifically active in cells that have impaired repair of DNA by the homologous recombination (HR) pathway. Cells with mutated BRCA function have HR deficiency, which is also present in a significant proportion of non BRCA-mutated ovarian cancer. Design In the last decade olaparib, the first and most-investigated oral PARP inhibitor has undergone phase I-III trials as a single agent, in comparison to and in addition to chemotherapy, and as a maintenance therapy following chemotherapy.
Introduction:
The introduction of platinum-based drugs and paclitaxel were landmark developments in the treatment of ovarian cancer. However, there has been little progress in the results of first-line therapy for more than a decade, and long-term survival improvements seen during this time have been due to better treatment of recurrent disease. Progression-free survival (PFS) in 'platinum-sensitive' relapsed ovarian cancer treated with platinumcombination therapies has remained relatively unchanged [1] , and around 11 months, but women are being offered a greater number of lines of treatment.
During this time maintenance therapy to delay progression and re-treatment with chemotherapy has evolved as a new therapeutic approach. Inhibition of angiogenesis [2, 3] and DNA repair pathways are two strategies that have led this development. The second is exemplified by inhibitors of PARP (poly ADP ribose polymerase) an important enzyme activated in response to singlestrand damage of DNA. It was originally believed that PARP inhibitors could be used to potentiate chemotherapy [4] , but the observation that the survival of cells with homozygous mutations of the BRCA1 or BRCA 2 genes is significantly impaired by PARP inhibitors [5, 6] has opened new treatment opportunities for ovarian cancer. Cells with defective BRCA proteins are deficient in the repair of double-stranded DNA breaks by homologous recombination (HR) and rely on other pathways to repair DNA damage, notably the PARP pathway that detects single DNA strand breaks and activates a number of effector proteins to initiate repair. Inhibition of PARP in the presence of HR deficiency (HRD) leads to cell death from gross genetic disarray due to a process called 'synthetic lethality' [7] . Several PARP inhibitors are being evaluated in ovarian cancer. Initial studies were in BRCA deficient tumours but as knowledge of the molecular and genetic biology has increased, studies are being extended to include a larger group of ovarian tumours.
Early clinical trials with PARP inhibitors:
Olaparib, (AZD2281) is a potent small-molecule oral PARP inhibitor and was the first to enter clinical trials in ovarian cancer and show clinical activity in women with BRCA1 or BRCA2 mutations. Tumour responses were seen during the first dose escalation studies and many of these patients who had previously been treated with several lines of therapy had durable responses.
The key side effects seen in some patients were fatigue (30%), nausea (32%) and anaemia (5%) [8] . In the 19 patients with a BRCA1/2 mutation (which included ovarian, breast and prostate cancer), 63% had a clinical benefit from olaparib treatment with radiological or tumour-marker responses, or disease stabilisation for a period of 4 months or greater. In an expansion phase in ovarian cancer, there was a 40% response-rate [9] . Response-rates were associated with the platinum-free interval, with an overall clinical benefit rate of 69.2%, 45.8% and 23.1% in the 'platinum-sensitive' (defined as recurrence six or more months after prior platinum therapy), 'platinum-resistant' (defined as recurrence less that six months after prior platinum therapy) and 'platinumrefractory' groups respectively. Although responses were seen at 100 mg twice daily a multicentre phase II study was undertaken to assess the efficacy and safety of oral olaparib monotherapy at the maximum tolerated dose (400 mg twice daily. Two cohorts of heavily pre-treated patients with a median of three previous chemotherapy regimens (range 1-16) and BRCA1/2 mutations were enrolled. An objective response was observed in 33% of patients in the 400 mg twice daily regimen and 13% of the 100 mg twice daily group, with a median PFS of 5.8 months (95% CI 2.8-10.6) and 1.9 months (95% CI 1.8-3.6) respectively [10] . mg, olaparib 400 mg, and PLD groups, respectively, with no statistically significant difference in PFS (hazard ratio (HR), 0.88; 95% CI, 0.51 to 1.56; p = 0.66) for the combined olaparib doses versus PLD [11] . The overall response rates by RECIST were also not significantly different (25%, 31%, and 18% for olaparib 200 mg, olaparib 400 mg, and PLD, respectively). Whilst the activity of olaparib was as anticipated from the phase I/II trials, the response to PLD in patients with a BRCA1/2 mutation was greater than expected. Subsequent retrospective data have confirmed that patients with recurrent ovarian cancer and a BRCA1/2 mutation respond well to PLD [12] , a drug that causes DNA damage that is less well repaired in tumours with HRD.
During this time, other phase II studies were performed that included women with recurrent ovarian cancer without a BRCA mutation. Emerging data from
The Cancer Genome Atlas study suggested that HRD could be more widespread in ovarian cancer, particularly in high-grade serous tumours that are sensitive to platinum-based treatments [13] . A phase II study in recurrent ovarian cancer confirmed this; 11 out of 46 patients (24%; 14-38) without a BRCA mutation responded to olaparib [14] .
Maintenance therapy
The concept of evaluating olaparib as a maintenance therapy to extend PFS in recurrent ovarian cancer arose from the aforementioned data. A randomised trial, 'study 19' was launched in 2008 to measure the PFS following the addition of olaparib or placebo maintenance therapy following the completion of platinum-based chemotherapy for platinum-sensitive high grade serous relapsed ovarian, fallopian tube or peritoneal cancer. A minimum of two prior platinum containing regimens was required for study entry, and the median number of regimens received in both arms was three.
In the 265 randomised patients BRCA status was known in 38%. The primary endpoint was PFS, which was significantly increased by olaparib, 400 mg bd [HR 0.35; 95% CI, 0.25-0.49; p<0.00001], extending the median time to progression or death following chemotherapy by 3.6 months (from 4.8 to 8.4 months) [15] . An early evaluation of overall survival (at 38% maturity) showed no difference, and this led to a temporary cessation of the development of olaparib, as it was felt unlikely that it would be approved by regulatory authorities. However, in a pre-planned subgroup analysis it appeared that there might be a survival benefit in the subgroup with a known BRCA There was no significant difference in overall survival at the second interim analysis (58% maturity). For the whole group the hazard ration was 0.88 (95% CI 0·64-1·21; p=0·44); similar findings were noted for patients with BRCAm (HR 0·73 [0·45-1·17]; p=0·19). However, the detection of differences in survival is confounded by crossover to a PARP inhibitor at a later date in 23% of patients taking placebo. The study confirmed that olaparib is well tolerated by most patients with fatigue, nausea and anaemia accounting for the greatest differences in side-effects compared to placebo. Dose interruptions due to side-effects occurred in 36% of those taking olaparib compared to 16% of patients on placebo. Similarly, dose reductions were more common in women taking olaparib than placebo, 42% versus 22 %, respectively. Nine patients taking olaparib discontinued treatment due to adverse events compared with 2 in the placebo group.
It is well known that even large differences in PFS do not often result in significant differences in OS due to the effect of post-progression therapies and crossover. Consequently, the European Medicines Agency (EMA) proposed that the time to subsequent progression after next-line therapy, (PFS2) could be accepted as a secondary supportive regulatory endpoint to PFS [17] . or somatic BRCA mutation [19] and many of these women do not have a family history of cancer [20] . Strategies for introducing routine BRCA mutation testing are being incorporated by individual countries. Their implementation can be complex; the cost of testing, involvement of local genetics units and social implications of identifying germline mutations all need to be taken into consideration. Furthermore, testing only for germline BRCA mutations will miss somatic mutations that may be present in 5-6% of these tumours [21, 22] .
Development strategies of PARP inhibitors in ovarian cancer:
The promising results seen with the early studies using olaparib, and temporary cessation of the development of olaparib announced in December 2011 led other manufactures of PARP inhibitors to develop similar a maintenance programme (TABLE 1) . Both niraparib and rucaparib have been shown to be active in patients with a BRCA1/2 mutation [23, 24] . Both maintenance studies are including patients without a BRCAm, to test the effect of PARP inhibitors in the BRCA wild-type population, incorporating a companion diagnostic test for HRD. The SOLO1 trial with olaparib tablets has a similar design to SOLO2 but is evaluating the role of olaparib maintenance in the first-line setting. There continues to be interest in combining PARP inhibitors with chemotherapy. Although olaparib combined with carboplatin and paclitaxel for platinum-sensitive recurrent disease increased PFS over chemotherapy alone, the results did not suggest an additive effect of olaparib and chemotherapy; the dose and schedule of both carboplatin and olaparib had to be altered to reduce toxicity [25] . However, veliparib in combination with carboplatin and paclitaxel is being evaluated in a three-arm trial (GOG 3005), comparing veliparib with chemotherapy, and also as maintenance in the first line treatment of ovarian cancer. In 2015 rucaparib was given 
